
Marta Casarrubios GarcÃ-a

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3771095/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial). Journal of Clinical Oncology, 2022, 40, 2924-2933.	1.6	127
2	Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clinical and Translational Medicine, 2021, 11, e491.	4.0	26
3	Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. Clinical Cancer Research, 2021, 27, 5878-5890.	7.0	30
4	Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. , 2021, 9, e002804.		5
5	Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 1413-1422.	10.7	475
6	Pro-inflammatory tumour profile predicts complete pathological response to neoadjuvant chemoimmunotherapy. , 0, , .		0